Af­ter a $200M fi­nanc­ing, High­land Ther­a­peu­tics falls silent on AD­HD drug’s fate as PDU­FA sails by

Back at the be­gin­ning of this year, the folks at Toron­to-based High­land Ther­a­peu­tics cel­e­brat­ed a $200 mil­lion fi­nanc­ing com­plet­ed through Mor­gan Stan­ley. That cash, they said, would go to com­mer­cial­iz­ing their AD­HD drug HLD200 through their whol­ly owned sub­sidiary Iron­shore, tout­ing a drug they have fre­quent­ly her­ald­ed as a break­through in the field as it faced a Ju­ly 30 PDU­FA date. They even hired some Shire vets to help grab mar­ket share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER